The investigators will perform a prospective randomized comparison between 3D and 2D laparoscopic total gastrectomy with splenic hilum lymph nodes dissection.
A prospective randomized comparison of 3D and 2D laparoscopic surgery for advanced gastric cancer with spleen-preserving splenic hilum lymph nodes dissection will be performed, to evaluate the safety and feasibility for the extensive application of the novel 3D laparoscopic technique. The evaluation parameters are number of group No.10 lymph nodes harvested, perioperative clinical efficacy, postoperative life quality and 3-year survival and recurrence rates.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
480
When participants with advanced proximal gastric cancer are randomized in the 3D laparoscopic-assisted totalgastrectomy (3D-LTG) group, they will received 3D-LTG with spleen-preserving splenic hilum lymph nodes dissection
When participants with advanced proximal gastric cancer are randomized in the 2D laparoscopic-assisted totalgastrectomy (2D-LTG) group, they will received 2D-LTG with spleen-preserving splenic hilum lymph nodes dissection
Chinese PLA General Hospital
Beijing, China
Number of splenic hilum lymph nodes harvested
Time frame: 7 days
Early complication rate
The early complication rate is defined as the event observed during operation and within 30 days after surgery.
Time frame: 30 days
Operative time
It will be assessed with the unit of "minute".
Time frame: Intraoperative
Operative blood loss
It will be assessed with the unit of "ml".
Time frame: Intraoperative
Time of splenic hilum lymph nodes dissection
It will be assessed with the unit of "minute"
Time frame: Intraoperative
Number of total lymph nodes harvested
Time frame: 7 days
Poster-operative recovery course
Time to first ambulation (unit of hour), flatus (unit of hour), liquid diet (unit of hour) and duration of hospital stay (unit of day) are used to assess the postoperative recovery course.
Time frame: 30 days
Quality of life
It will be assessed with questionnaire of "WHO-QOL-100" (WHO was short for world health organization)
Time frame: 1 year
3-year disease free survival rate
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
3-year overall survival rate
Time frame: 3 years